Although early clinical trials showed that NGF specifically affected AD patients, NGF cannot pass through the blood–brain barrier (BBB), and direct injection of NGF may cause adverse effects, such as pain and weight loss [2,168,169]. The gene discussed is NGF; the disease is Alzheimer disease.